Safety and efficacy study of CF101 to treat psoriasis

Journal of Drugs in Dermatology, March, 2008

Sponsored by: Can-Fite BioPharma. This study will test the hypothesis that CF101, an agonist to the A3 adenosine receptor, which is under development to treat other immune-mediated inflammatory diseases, will provide clinical benefits in the treatment of chronic plaque psoriasis. Patients with psoriasis who qualify for the study will be treated with twice-daily CF101 capsules or placebo capsules for 12 weeks. The safety of treatment will be carefully assessed through clinical and laboratory monitoring. The effect of treatment on psoriasis will be evaluated through standard techniques of examination and measurement of the severity of skin involvement.

Condition         Intervention  Phase

Plaque Psoriasis  Drug: CF101   Phase II

Study ID Numbers: CF101-201PS

ClinicalTrials.gov Identifier: NCT00428974